13F Holdings
中文EN

TENX TENAX THERAPEUTICS, INC.

Pharmaceutical Preparations · Nasdaq · SEC CIK 34956 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY0.4%
TTM EPS YoY-87.8%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-64.2%
ROA-59.8%
ROIC (approx.)—
Asset turnover0.00x

Leverage & solvency

Liabilities / assets7.1%
Debt / equity0.00x
Current ratio14.01x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.75x
Accruals ratio-14.9%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$0$0———
R&D expense$32.67M$12.71M$3.23M$5.38M$25.15M
SG&A expense$23.71M$6.79M$5.00M$5.68M$7.58M
Operating income-$56.38M-$19.49M-$8.23M$11.05M-$32.73M
Interest expense$0$23,000$24,000$4,443$949
Income tax$0$0$0$0$0
Net income-$52.60M-$17.60M-$7.71M$11.05M-$32.47M
EBITDA—-$19.49M-$8.23M$11.06M-$32.72M
EPS (basic)-1.34-1.15-31.04—-1.58
EPS (diluted)-1.34-1.15-31.04—-1.58
Weighted avg. shares (diluted)39.22M15.27M248,447—20.58M
Banking
Net interest income————$949
Balance sheet
Cash & equivalents$97.56M$94.85M$9.79M$2.12M$5.58M
Short-term investments————$0
Current assets$104.23M$96.69M$11.68M$3.21M$5.69M
PP&E, net——$0$7,189$7,108
Total assets$104.23M$96.69M$11.69M$3.40M$5.99M
Current liabilities$7.16M$4.69M$3.59M$1.85M$1.56M
Total liabilities$7.16M$4.69M$3.59M$1.91M$1.75M
Shareholders' equity$97.07M$91.99M$8.10M$1.49M$4.24M
Shares outstanding9.31M3.42M298,28128,6481.26M
Cash flow statement
Operating cash flow-$35.80M-$14.81M-$5.90M-$11.39M-$10.86M
Capital expenditure———$2,323$5,252
Free cash flow———-$11.39M-$10.86M
Investing cash flow—$0$3,000-$2,323$452,609
Financing cash flow$38.51M$99.87M$13.57M$7.93M$9.74M
Depreciation & amortization—$0$8,000$5,143$4,116
Stock-based compensation$19.16M$1.12M$191,000——

Free plan shows the latest 5 periods; Pro shows all 16 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.